1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Relationship between diabetes and its severity, frailty and adverse surgical outcomes among older adults with cancer
    Meeting Abstract

    Martes, J.; Tin, A. L.; Shahrokni, A.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Cell-free DNA analysis as a molecular tool to monitor response to immune checkpoint inhibition in endometrial cancer
    Meeting Abstract

    Manning-Geist, B.; Patel, J. A. A.; Marra, A.; Da Cruz Paula, A.; Hanlon, E. J.; Abu-Rustum, N.; Shah, R. H.; Berger, M. F.; Hensley, M. L.; Zamarin, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification
    Meeting Abstract

    Makker, V.; Perez-Fidalgo, J. A.; Bergamini, A.; Spitz, D. L.; Van Gorp, T.; Sehouli, J.; Klat, J.; Perri, T.; Oza, A. M.; Hogdall, E. V. S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician's choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775
    Meeting Abstract

    Makker, V.; Colombo, N.; Santin, A.; Miller, D. S.; Fujiwara, K.; Pignata, S.; Ray-Coquard, I. L.; Kim, Y. M.; Guerra, E. M.; Huang, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Molecular profile and clinical outcomes of renal cell carcinoma brain metastases treated with stereotactic radiosurgery
    Meeting Abstract

    Ma, J.; del Balzo, L.; Khaleel, S. S.; Flynn, J.; Zhang, Z.; Voss, M. H.; Freeman, B.; Hakimi, A. A.; Lee, C. H.; Eichholz, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205
    Meeting Abstract

    Lorusso, D.; Vergote, I.; O'Cearbhaill, R. E.; Westermann, A. M.; Banerjee, S. N.; Van Nieuwenhuysen, E.; Iglesias, D. A.; Collins, D. C.; Cibula, D.; Madsen, K.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer
    Meeting Abstract

    Lukashchuk, N.; Armenia, J.; Tobalina, L.; Carr, T. H.; Milenkova, T.; Liu, Y. L.; Penson, R. T.; Robson, M. E.; Harrington, E.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens
    Meeting Abstract

    Lu, J. M.; Kalinsky, K.; Tripathy, D.; Sledge, G. W.; Gradishar, W. J.; O'Regan, R.; O'Shaughnessy, J.; Modi, S.; Park, H.; McCartney, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Multimodal integration of radiology, pathology, and genomics for prediction of response to PD-1 blockade in patients with non-small cell lung cancer
    Meeting Abstract

    Luo, J.; Vanguri, R. S.; Aukerman, A. T.; Egger, J. V.; Fong, C. J.; Horvat, N.; Pagano, A.; Araujo-Filho, J.; Geneslaw, L.; Rizvi, H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04)
    Meeting Abstract

    Li, B. T.; Ahn, M. J.; Goto, K.; Mazieres, J.; Padda, S. K.; William, W. N.; Wu, Y. L.; Dearden, S.; Ragone, A.; Viglianti, N.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save